420 with CNW — Why Cannabis Firms Need to Give Branding Adequate Attention

A troubling tendency has surfaced in states where marijuana markets are regulated: businesses frequently offer their goods using identical or very similar trademarks. This overlap occurs because the United States Patent and Trademark Office (USPTO) prohibits federal trademark safeguarding for cannabis products, as they are illegal at the federal level.

In the absence of federal trademark safeguards, marijuana businesses are left with little choice if they want to prevent others from using identical brand names or logos in different states.

This situation has created a unique issue in the sector where customers question if a product is from Company A or Company B when packaging or branding looks nearly identical. As more states implement regulated markets, new brands arise, raising the possibility of consumer confusion and underscoring the importance of unique trademarks.

Typically, marijuana businesses select a name or logo for their product, assuming it’s unique and unused by others, often without conducting a thorough search. Regrettably, this presumption may result in expensive legal disputes. Many marijuana business owners have encountered challenges over the years after discovering that their “unique” terminology, such as Dank, Emerald, Elevated, Canna, or 420, were already commonly used or connected to cannabis culture.

Businesses in the cannabis industry must therefore negotiate a challenging environment where trademark conflicts are inevitable until laws at the federal level change and the USPTO approves trademarks for marijuana products.

Once this happens, the shift will be both advantageous and difficult. The market will become more competitive as a result of the opening of the floodgates for new trademark applications, even though businesses will now have recourse to federal courts for trademark safeguarding.

In the interim, cannabis businesses should look at alternative brand protection strategies. Federally, trademarks are accessible for goods and services that do not directly involve the cannabis plant, such as select hemp-based goods, websites, smoking accessories, retail services, and non-infused products.

Cannabis companies can pursue trademark safeguarding in states where cannabis is regulated for their in-state offerings, like retail services, edibles, or flowers. However, these protections are limited to the state of registration, unlike federal trademarks, which cover the entire U.S., creating issues for companies that operate across state lines.

To further safeguard their brand, companies should consider other forms of intellectual property protection, such as patents, copyrights, or trade secrets.

One common misconception is that if a company hasn’t faced a trademark lawsuit yet, it won’t face one in the future. However, as the industry grows, litigation around trademark issues is expected to rise, with larger companies often leveraging their resources to protect their trademarks. When enforcement happens, smaller businesses may face the difficult choice between rebranding or engaging in a legal fight.

Many companies want the trademark to represent their product, but a more effective trademark reflects the company’s unique character, values, and purpose. A unique trademark enhances a brand’s long-term standing and helps it stand out in the marketplace.

It is also easier to defend, which makes it more difficult for rivals to violate the brand and guarantees greater recognition and protection.

With the proposed reclassification of cannabis to Schedule III and the evolving legal status of cannabinoids, more entrepreneurs are likely to enter the market, leading to a wave of new brands. In this dynamic landscape, a robust trademark is not just a logo—it protects a company’s identity. Starting early on trademark safeguarding can mean the difference between a smooth path to growth and facing costly legal obstacles.

For established companies like Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF), protecting their brand identity is paramount since these entities have worked hard to get to where they currently are.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Scientific Review Finds Marijuana Lowers Chronic Nerve Pain

A recent review highlights the promising effects of cannabinoids, a compound in cannabis, in managing persistent nerve pain. According to the research, cannabinoids may offer substantial pain relief with few or no side effects, suggesting a valuable alternative to conventional pain medications for patients dealing with persistent nerve pain.

Published in the Cureus journal, the review underscores the positive impact of cannabinoids on pain control, noting their benefits as a more natural option compared to synthetic drugs. This could make cannabinoids an attractive option for people seeking alternatives to traditional medications.

The research team, which sifted through numerous studies, narrowed their focus to five randomized, placebo-controlled trials conducted from 2000 to 2024. Their findings show that patients receiving cannabinoid treatment reported significantly higher pain relief than those given a placebo.

According to the study, cannabinoids led to pain relief in about 33% of participants, compared to just 15% in the placebo group, as measured by an analogous analog scale. For individuals experiencing sharp, intense pain, using CBD in a topical form provided even more relief, based on a neural pain scale. Importantly, very few side effects were reported, underscoring cannabinoids’ potential advantages in pain treatment.

According to the study, for those suffering from neuropathic pain—a type of pain caused by nerve damage often related to HIV/AIDS, diabetes, multiple sclerosis, shingles, and sometimes as a side effect of specific medications or radiation—finding effective treatments is complex. Such conditions often require specialized care and intensive medication regimens. In this context, cannabinoids may represent a breakthrough in pain management, offering a potentially more accessible and natural alternative for long-term relief.

The researchers acknowledge that more data is needed to understand the long-term side effects and potential interactions of cannabinoids, particularly due to varying legal restrictions and societal attitudes worldwide. Despite these challenges, they point out that cannabinoids may offer a new approach to chronic pain treatment, standing out as a natural remedy with minimal adverse effects.

The study also calls for further clinical trials to determine the most effective formulations and dosages of marijuana-derived medications for managing chronic pain.

As medical cannabis continues to gain legal acceptance in various states, chronic pain is among the top reasons for its medical use. Reports from both healthcare providers and patients suggest that marijuana can be a powerful alternative for pain management, reinforcing the case for it to be more widely considered in pain treatment strategies.

Companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) that believe in the therapeutic potential of marijuana and its compounds will be pleased that many recent studies, such as this review, are confirming the medicinal attributes of marijuana.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Delaware Cannabis Business Sites Dwindle as Local Bans Take Effect

Last year, when Delaware legalized cannabis, legislators approved the opening of 30 retail cannabis stores across the state. However, despite licenses being expected this year and stores potentially launching by 2025, available locations for shoppers to purchase cannabis legally are declining.

Several cities and towns in the state have used a provision in the legalization law to ban marijuana retail outlets, along with testing, cultivation, and manufacturing facilities. Sussex County has enforced bans in towns such as Bridgeville, Seaford, Millsboro, and Dagsboro. Beach towns like Milton, Rehoboth, South Bethany, Dewey, Bethany, Lewes, Fenwick Island, and Ocean View have also opted out of allowing cannabis businesses.

Additionally, Middletown, Delaware’s fourth-biggest city, has passed a total ban on cannabis businesses, while Newark has made an exception for its Main Street shopping area. Dover, the second-biggest city in the state, is also considering limitations on where marijuana stores can operate.

Sussex County Council is utilizing another legal provision that enables counties to regulate aspects such as the number and location of cannabis businesses. The council has restricted cannabis stores to C3-zoned areas, which are designated for heavy commercial use. However, the law also prohibits any cannabis businesses from being within three miles of municipalities, churches, schools, or drug abuse treatment centers.

This zoning restriction effectively results in a ban on retail marijuana stores in the county since all of the C3-zoned areas are within three miles of restricted areas, leaving no viable locations for these businesses.

Meanwhile, in Wilmington, the mayor’s office issued a statement in September outlining its approach to cannabis businesses. Cannabis entrepreneurs would have little trouble opening their enterprises in different parts of the city if there were no local prohibitions.

The mayor, however, has expressed his intent to restrict cannabis businesses from operating near schools or neighborhoods. The proposal initially sought to ban these businesses within 100 feet of schools or residential areas. Permitted zones would include manufacturing districts, downtown retail areas, and commercial centers. However, the restricted zone was extended by the city’s planning commission to 300 feet, but it will be reviewed again this month before the council makes a final decision.

In New Castle County, the only current restrictions being considered are that cannabis stores cannot operate within 1,000 feet of places like schools, daycare centers, churches, parks, government offices, or drug treatment centers.

State Representative Ed Osienski, who sponsored the cannabis regulatory and legalization bills, has expressed frustration with the actions taken by most local governments. He stated that the original intent of the law was to treat cannabis stores similarly to liquor stores, which are common throughout the state.

Meanwhile, Robert Coupe, Delaware’s cannabis commissioner, has remained focused on processing license applications while staying neutral on the local zoning issues. Coupe acknowledged the difficulties created by these local restrictions, especially in Sussex County, but also noted that New Castle and Kent counties seem to be imposing fewer hurdles for cannabis retailers.

While the situation in Delaware is still very much in flux, industry actors like SNDL Inc. (NASDAQ: SNDL) from around the country that hoped for widespread access to adult-use marijuana products by adults wishing to consume those products could be getting concerned by the restrictive actions of local authorities with regard to potential locations for cannabis businesses.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Poll Predictions Suggest Florida Marijuana Measure Will Pass

A recent poll indicates that voters in Florida are likely to approve two highly debated measures on the upcoming November ballot: recreational cannabis and abortion rights.

The poll, conducted by the Public Opinion Research Lab (PORL) at the University of North Florida, was released on Monday and shows strong support for both measures. Specifically, 66% of voters back Amendment 3, which aims to legalize recreational marijuana, while exactly 60% of voters are in favor of Amendment 4, which would secure the right to abortion.

For an amendment to be added to Florida’s Constitution, it requires at least 60% voter approval statewide. The poll, which comes with a margin of error of about 3.5 percentage points, suggests that both amendments are on track to meet this threshold.

Michael Binder, a professor of political science and the director of PORL, commented on the survey stating that after years of Floridians polling on cannabis legalization, it’s evident that the majority of voters are in favor. Binder also noted that support for legalization has risen slightly, gaining two percentage points since the last PORL survey conducted in July, where 64% of voters expressed their intention to vote “yes.”

While support for Amendment 3 has increased, the abortion rights measure has just barely crossed the 60% threshold, according to Binder. Currently, 32% of respondents are opposed to Amendment 4, while 8% remain undecided.

The survey results come at a time when Governor Ron DeSantis and his administration have been actively opposing both initiatives. The governor has even used public funds to finance public service statements from state agencies that criticize the amendments. This has sparked several legal battles aimed at stopping the amendments, though most have been unsuccessful so far.

Additionally, the Florida Department of State recently published a report accusing the group behind the abortion rights amendment of fraudulent practices during the petition-gathering process. The group denies any misconduct, and the report led to a lawsuit filed by an anti-abortion organization seeking to invalidate the results of the votes on the measure.

The PORL survey polled 977 likely voters between October 7 and 18, targeting individuals from the state’s 10 key media markets. The sample was drawn from the state’s September 2024 voter file and included both mobile and landline phone numbers. To qualify for the poll, voters had to have participated in one of Florida’s general elections in 2016, 2018, 2020, or 2022, or the state’s primary elections in 2020, 2022, or 2024. Those who indicated that they would “definitely”or “probably” not vote in the November election were excluded.

If the adult-use legalization measure passes, the launch of recreational cannabis sales is likely to expand the business opportunities available to not only plant-touching marijuana companies but also other ancillary entities, such as those operating on the same model as Innovative Industrial Properties Inc. (NYSE: IIPR).

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Arkansas Supreme Court Says Cannabis Amendment Ballots in November Will Not Count

The Arkansas Supreme Court decided in a narrow 4-3 ruling that votes in favor of and against a plan to broaden the state’s medical cannabis program would not be taken into account. Protect Arkansas Kids, a nonprofit that joined the legal fight against the amendment—Issue 3, filed a case that resulted in this decision. The votes cast on Issue 3 will be ignored, even though it will still be on the ballot in November.

The amendment sought to introduce several modifications to the state’s medical cannabis system, which was initially approved in 2016. It sought to ease licensing rules, widen the range of qualifying illnesses and medical professionals authorized to prescribe cannabis as well as permit patients to grow their marijuana at home.

However, in its decision, the court rejected Secretary of State John Thurston’s initial complaint. The main argument of the complaint focused on paid canvassers’ training requirements. Thurston contended that the group supporting the proposal, Arkansans for Patient Access, did not reach the required 90,704 valid signatures to qualify for the ballot due to non-compliance with state laws related to canvassers’ training.

In his majority opinion, Justice Shawn Womack supported a second legal complaint that argued the proposal’s ballot title and popular name were inadequate. Justice Womack also objected to a clause in Issue 3 that would have permitted the holding of up to one ounce of cannabis if it were to be legalized federally. He argued that this provision was misleading, as it would apply even to those without a medical cannabis prescription, contradicting the popular name, which solely references medical cannabis.

Womack was joined in the majority opinion by Justices Bilenda Harris-Ritter, Barbara Womack Webb, and Don Curdie.

Meanwhile, Justices Cody Hiland, Rhonda Wood, and Karen Baker dissented from the majority ruling. Hiland contended that the initiative’s ballot title and popular name were neither insufficient nor misleading. He argued that the court’s long-standing legal standard for determining the sufficiency of ballot titles had been disregarded in this case and that voters should have been allowed to decide on the initiative.

Arkansans for Patient Access expressed disappointment over the court’s decision, calling it a setback for the state’s medical cannabis program. They reaffirmed their commitment to removing barriers for patients and reducing costs while accusing anti-cannabis politicians of ignoring the will of the people.

Conversely, Protect Arkansas Kids praised the ruling describing the ballot initiative as misleading. They claimed it was part of a broader effort by the cannabis industry to legalize potent, addictive drugs under the pretense of medicine.

The ruling is likely to be a disappointment to the broader cannabis industry, including firms from across the border like Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) since the issues that the ballot measure was seeking to address will persist until the next election cycle when campaigners can launch another attempt to enact change.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — NIH Says Oncologists Aren’t Equipped to Answer Cancer Patients’ Questions on Medical Marijuana

Recent research highlights the increasing use of marijuana among individuals undergoing cancer treatment and the associated implications of this trend. Various studies indicate that approximately 20%-40% of cancer patients turn to cannabinoids or medical marijuana to alleviate side effects such as stress, anxiety, insomnia, pain, and nausea.

The surge in marijuana use among cancer patients aligns with the rise in states that have legalized it for medical purposes. However, research into the safety and efficacy of which marijuana products can be used for managing side effects and symptoms associated with cancer has not kept pace.

In March this year, the American Society of Clinical Oncology (ASCO) released its first clinical marijuana use guidelines stating that the access and utilization of marijuana and/or cannabinoids by cancer adult patients had outstripped the body of research supporting their clinical applicability.

A significant issue stemming from this gap in scientific knowledge is that many cancer care professionals, including oncologists, feel unprepared to discuss medical marijuana with their cancer patients. One study revealed that while almost 40% of surveyed oncology nurses and oncologists felt comfortable providing advice on marijuana use, just roughly 13% considered themselves knowledgeable about it.

The studies, which were conducted at cancer centers recognized by the National Cancer Institute (NCI) and funded by the organization, were published as a group in JNCI Monographs in August.

For many years, cancer patients have turned to marijuana to alleviate various symptoms associated with cancer and other illnesses. However, until recently, such practices were largely illegal in the U.S. Even now, marijuana remains a Schedule I drug, which means it is still federally illegal. Yet, 24 states plus DC have legalized it for both medical and recreational use.

Approximately 75% of Americans now reside in a state where marijuana is legal in some capacity, per a Pew study. Furthermore, access to marijuana has become widespread, with roughly 15,000 dispensaries across the country.

While access to marijuana has grown, questions about its safety remain. One of the primary concerns is the potential interaction between marijuana and cancer treatments. Some small studies suggest that marijuana could reduce the effectiveness of immunotherapy treatments. Additionally, marijuana has sedative properties and may amplify the effects of other medications that cause drowsiness, increasing the risk of accidents or falls.

Despite these concerns, many patients believe the marijuana benefits outweigh its risks. This can make it challenging for healthcare providers to discuss the potential harms and the lack of robust scientific evidence with patients who may already have preconceived positive opinions about its use.

Experts advise healthcare providers to review the ASCO guidelines and stay updated on the growing body of research into the physiological and biological effects of marijuana. Furthermore, they recommend that cancer patients inform their oncologists of any supplements they are using, including marijuana products.

Studies, however, indicate that this is not occurring as frequently as it ought to—the JNCI study found that just 20% of marijuana users reported talking to their oncologist about their use.

The marijuana industry, including enterprises like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) would be comfortable when oncologists get ample information about the medicinal use of cannabis by cancer patients so that the best advice can be given by these professionals who are responsible for overseeing the treatment and management of issues arising after a cancer diagnosis.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Federally-Financed Studies Reveal Developmental Issues or Autism Aren’t Linked to Maternal Marijuana Use

Two new studies funded by the federal government may help reduce some concerns about cannabis use during pregnancy. One study found no link between early cannabis use in pregnancy and the development of autism in children, while the other showed no connection to an increased risk of developmental delays in early childhood.

Both studies analyzed pregnancy outcomes where the mother either self-reported marijuana use or tested positive for THC during prenatal visits, typically around the second month of pregnancy.

The autism-related study included information from 146,296 individuals involved in 178,948 pregnancies from 2011 to 2019. The study on developmental delays included information from 106,240 adults and 119,976 pregnancies from early 2015 to late 2019. The kids underwent tests at different phases to check for developmental milestones and autism.

The autism study concluded that prenatal marijuana use was not linked to childhood autism after accounting for factors such as socioeconomic status, other substance use, and maternal health conditions. Likewise, the developmental delay study found no evidence that cannabis use in early pregnancy was associated with delays in motor skills, speech or language, or overall developmental impairment.

However, both studies caution that the results should not be interpreted as indicating that marijuana use during pregnancy is entirely safe, especially with heavy or frequent use. The autism study’s authors did note that, despite the lack of a general link to autism, there might be one with frequent cannabis use, underscoring the need for additional investigation in this field.

One notable finding in the developmental study was a slight reduction in speech and language delays when only urine test results were considered for cannabis use. This finding did not appear in the self-reported data on marijuana use.

The studies also align with recommendations from both the American Academy of Pediatrics and the American College of Obstetrics and Gynecology, which advise pregnant people to avoid marijuana use. The authors recommend that people who are pregnant or planning to become pregnant should be informed of the potential risks marijuana poses to fetal and newborn health.

The research teams stated that their work represents one of the largest investigations into maternal cannabis use during pregnancy. While their results are consistent with most studies on childhood development following prenatal cannabis use, the researchers acknowledged that some earlier research had suggested a negative impact. They also pointed out that their findings differ from a 2023 study that reported a connection between cannabis use and autism in children.

These studies align with what many in the cannabis industry, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), have always wanted government-funded studies to reaffirm so that the claims by prohibitionists are proved wrong.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Benzinga Cannabis Conference Shows How Businesses Are Struggling in the Legal Grey Area

Last week’s Benzinga cannabis conference, held in downtown Chicago, offered a glimpse into an industry that is anxiously awaiting full legal recognition.

The event seemed, at first appearance, to be very similar to most business conferences. There were notably fewer women in the gathering than men, who made up the majority of those in suits. While many participants left with complimentary T-shirts or tote bags, there was no overt smell of cannabis in the venue. However, it was more difficult to locate actual cannabis on-site.

Most of the people present had experience in traditional corporate settings before transitioning into the marijuana space. Many had backgrounds in industries like alcohol, law, or medicine. Surprisingly, several marijuana company CEOs admitted they had never personally tried marijuana until they began working in the industry.

The conference covered a variety of topics, from taxation to lobbying efforts. However, speakers occasionally touched on the reality that thousands of individuals have been imprisoned for participating in the illegal cannabis trade. These individuals, who are often left out of the conversation, would likely never get to attend such events.

In addition to broader legal challenges, the inconsistency of cannabis regulations across different states also poses significant hurdles for the sector.

For instance, designer Dang Nguyen of The Packaging Company shared that he often has to create multiple versions of the same packaging to meet diverse state cannabis requirements. Some states mandate that warning labels cover a significant portion of the package design, while others prohibit the use of bright or attractive colors on packaging.

The complex regulatory environment has even given rise to new industry sectors. Certainty Labs’ creator, Brandy Young, launched her company when recreational marijuana became legal in New York. Her lab specializes in third-party testing, which is required by law to guarantee that marijuana products have proper potency labels and do not contain harmful levels of contaminants like heavy metals or pesticides.

However, Young pointed out that labs face criticism from both within the industry and from consumers. “Regulators place us in a role where we’re seen as policing the industry, but that’s not our purpose,” she explained. On top of that, labs can lose credibility with consumers due to incidents like a recent exposé by the Los Angeles Times, which revealed that some marijuana products contained harmful chemicals that did not show up in lab tests.

For many marijuana businesses struggling to stay afloat, the hope is that federal legalization could bring financial security and stability. However, according to some experts, this could come with its own set of problems, such as higher taxes. Nonetheless, the entire industry, including firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), would appreciate a uniform regulatory structure across the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Says Medical Cannabis Promotes a Higher Level of Physical Activity

A recent study published in the Cannabis Research Journal challenges the outdated stereotype that cannabis users, often labeled as “lazy stoners,” are less active. The research shows that medical cannabis promotes increased physical activity in individuals with chronic health issues, while recreational marijuana boosts physical activity even more, particularly in those without chronic conditions.

The study examined data from adults aged 18 and over across the United States between 2016 and 2022. The researchers analyzed information collected by the CDC’s Behavior Risk Factor Surveillance System, which conducts nationwide phone surveys focused on health-related behaviors, preventive health services, and chronic illnesses.

One of the key findings was that people who reported using cannabis were more physically active than those who didn’t, but this difference was most pronounced in areas where cannabis is legally available, either for medical or recreational use. The study did not find a strong link between medical marijuana use and increased physical activity. However, physical activity was a more common reason for recreational use.

The authors suggest that when people use cannabis to enhance physical activity, it might be because it helps them focus, boosts enjoyment, or strengthens the connection between the mind, body, and spirit. Cannabis may also aid in rehabilitation by enhancing sleep and lowering discomfort.

Although medical cannabis users did not list physical activity as a primary reason for use, the researchers proposed that cannabis might indirectly help those with chronic illnesses stay more active by alleviating some of their symptoms.

Paul Armentano, Deputy Director of NORML, commented on the study, highlighting how it goes against long-standing assumptions about cannabis users. He noted that the results challenge the false stereotype that marijuana consumers are unmotivated or lazy. He also expressed disappointment that these misconceptions have often shaped public health messages and have contributed to stigmatizing responsible marijuana use.

The study’s conclusions align with some previous research on the relationship between physical activity and cannabis use. For instance, a similar study conducted in Canada this year found that adults aged 18 to 50 who used cannabis were neither more inactive nor more intensely active than non-users.

However, the research did note a slight increase in light physical activity following marijuana use. The authors of that study argued that their findings contradicted concerns that marijuana use promotes a sedentary lifestyle. They emphasized that the traditional “lazy stoner” image fails to account for the many ways people use marijuana today.

According to another study published in February, people who use cannabis walk more often than non-users or e-cigarette users. The same study also discovered that cannabis users had the same likelihood of engaging in fundamental physical activities like strength training as non-users did.

Additionally, 2019 research suggested that people who use marijuana before or after exercise experience better workouts and recover more effectively. Overall, the growing body of research challenges traditional assumptions about marijuana users, showing that many incorporate it into an active and health-conscious lifestyle.

The entire cannabis industry, including leading companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY), may be pleased that yet another misconception about marijuana use has fallen apart in the face of rigorous studies conducted to understand the true effects of the substance.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW —South Dakota Voters Can Decriminalize Cannabis, Legislators Will Decide on Sales

The recreational cannabis ballot initiative in South Dakota, known as Initiated Measure 29 (IM 29), will not directly lead to the legalization of cannabis sales. For sales to become legal, further action from the state legislature would be required.

IM 29 primarily aims to decriminalize the use, possession and free sharing of up to two ounces of cannabis for individuals 21 years of age and older. Currently, possessing cannabis is considered a misdemeanor that could result in up to a year of jail time. The measure would also decriminalize cannabis edibles and concentrates, which are currently classified as felonies in the state, carrying potential prison sentences of up to five years.

Decisions regarding the establishment of a legal market for cannabis sales would be left to the state legislature during its annual lawmaking session, which runs from January to March.

The cautious approach to legalization is a result of a failed attempt in 2020 to legalize marijuana for both medical and recreational purposes in South Dakota. That effort, which was supported by a majority of voters, was struck down in court for violating the state’s rule for ballot initiatives. As a result, IM 29 focuses on legalizing distribution and possession while leaving the creation of a retail market for future legislative discussion.

A fiscal note prepared by the Legislative Research Council estimates that passing IM 29 could save South Dakota counties about $581,556 annually in costs related to prosecutions and incarcerations for misdemeanor marijuana offenses. However, the note does not address the potential savings from decriminalizing felony possession of concentrated marijuana.

House majority leader, Representative Will Mortenson, stated that he anticipates the legislature will deal with retail cannabis market regulation if IM 29 passes. The foundation has already been established. A law to regulate cannabis sales was passed by the state senate in 2022, but it was not approved by the house. Mortenson also notes that there is resistance to the legalization of cannabis, with certain legislators holding steadfast antilegalization stances.

Recent polling showed that 42% of voters supported IM 29, while 542% opposed it and 7% remained undecided.

Opponents have raised concerns about the increased potency of current cannabis, potential public-health risks and the possibility of higher crime rates in states that have legalized the drug. They contend that the cost of addiction treatment and law enforcement would exceed any tax income from the legal sales.

Supporters of IM 29 counter these arguments, however, pointing out that states with legalized cannabis have already collected billions in taxes. Additionally, they emphasize that IM 29 would still prohibit driving while intoxicated and that legalization would grant legislators the authority to control the potency of cannabis products.

Companies with interests in the marijuana industry, including Innovative Industrial Properties Inc. (NYSE: IIPR), will be watching to see whether the voters of South Dakota finally get a chance to legally access recreational marijuana.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com